title: One-year outcome from an all-comers population of patients with ST-segment elevation myocardial infarction treated with biolimus-eluting stent with biodegradable polymer.
abstract: OBJECTIVE
  To evaluate the performance of biolimus-eluting stent (BES) in patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) in a real world clinical scenario.
  
  
  BACKGROUND
  Randomized studies suggest that the BES with biodegradable polymer is more effective and safe than early generation coronary stents in patients with STEMI.
  
  
  METHODS
  We included all consecutive STEMI patients undergoing PCI in this prospective, multicenter registry. The primary endpoint of the study was the rate of major adverse cardiac events (MACE), a composite of cardiac death, recurrent myocardial infarction and ischemia-driven target vessel revascularization at 1-year follow-up.
  
  
  RESULTS
  Between June and December 2012 we enrolled 311 STEMI patients. The primary endpoint occurred in 3.2% (95% confidence interval: 1.6-5.8) of patients: cardiac death, re-infarction, and ischemia-driven TVR occurred in 2.3%, 1.3%, and 0.6% of patients, respectively. One-year MACE-free survival was 96.8% ± 1.0%.
  
  
  CONCLUSIONS
  In a real-world cohort of STEMI patients undergoing PCI, the use of BES is associated with good 1-year clinical outcome. These results confirm and expand previous findings showing the efficacy and safety of BES in the setting of randomized trials.
authors.affiliation: Department of Cardiovascular Sciences, European Hospital, Rome, Italy.
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Tomai
authors.forename: Leonardo
authors.initials: L
authors.lastname: De Luca
authors.forename: Luca
authors.initials: L
authors.lastname: Altamura
authors.forename: Francesco
authors.initials: F
authors.lastname: Versaci
authors.forename: Mauro
authors.initials: M
authors.lastname: Pennacchi
authors.forename: Igino
authors.initials: I
authors.lastname: Proietti
authors.forename: Anna S
authors.initials: AS
authors.lastname: Ghini
authors.forename: Pierfrancesco
authors.initials: P
authors.lastname: Corvo
authors.forename: Giovanni
authors.initials: G
authors.lastname: De Persio
authors.forename: Alessandro
authors.initials: A
authors.lastname: Petrolini
authors.forename: Antonella
authors.initials: A
authors.lastname: Tommasino
authors.forename: Gennaro
authors.initials: G
authors.lastname: Sardella
mesh_terms: D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D018572:Disease-Free Survival; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D007558:Italy; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D011446:Prospective Studies; D011474:Prosthesis Design; D012008:Recurrence; D012042:Registries; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; C518022:umirolimus; D020123:Sirolimus
keywords: ST-elevation myocardial infarction; biodegradable polymer; biolimus-eluting stent; real-world registry